IMJUDO 20 mg / ml concentrate for solution for infusion

Licence status
Authorised: 20/02/2023
Active substances
Tremelimumab
Dosage Form
Concentrate for solution for infusion
Licence number
EU/1/22/1713/001-002
Licence holder
AstraZeneca AB

Product documents

Licence information

ATC code
L01FX20 tremelimumab, L01XC Monoclonal antibodies
Legal supply status
Product subject to prescription which may not be renewed (A)
Place of sale
Supply through pharmacies only
Conditions of Licence
Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Marketing availability
Unknown
Advertising conditions
Advertising to healthcare professionals only
Licence issued
20/02/2023

Educational materials for patients